ClinicalTrials.govpublic full text
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
hepatitis c, chronic, recurrent chronic hepatitis c, pharmacokinetics, simeprevir, daclatasvir, ribavirin, orthotopic liver transplantation, tmc435, bms-790052, rbv, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 838194
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.